Johnson & Johnson’s rumoured interest in Auris Health has been confirmed with a $3.3 billion buyout deal that boosts the group’s position in the fast-growing surgical robotics market.

The World Health Organization listed C. auris as a critical priority for research and public health action in 2022. The U.S. Centers for Disease Control and Prevention has also declared the fungus ...

Hospital researchers say the observed increase in clinical cases of the multidrug-resistant fungus mirrors national trends.

Lyell Therapeutics and Rakuten Medical all reached the $1 billion valuation mark. Some significant changes happened in 2019, with Auris Health getting bought by Johnson & Johnson for $3.4 billion ...

In a retrospective study, researchers found a 2,200% increase in clinical Candida auris infections at Miami-based Jackson ...

Johnson & Johnson MedTech has secured an FDA clearance for new artificial intelligence-powered guidance systems to support ...

C. auris is considered an urgent public health threat due to its resistance to multiple antifungal treatments and ability to spread quickly in healthcare settings, particularly among ...

A drug-resistant fungus, Candida Auris, is spreading rapidly in U.S. hospitals, posing a severe threat to patients who need ...

C. auris is also known to spread in hospitals and other health care facilities. The team wondered if it might be prevalent in nursing homes, as well. To find out, they collected samples from ...

Dublin, Feb. 18, 2025 (GLOBE NEWSWIRE) -- The "Laparoscopy Devices Patent Landscape Report" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive ...

Discover how new global guidelines aim to combat the rising threat of Candida infections with updated treatments and ...